This review highlights emerging therapeutic strategies for heart failure, including gene therapy, microRNA modification, and stem cell therapy.
Answers are grounded in this paper and cite their sources.
These strategies remain investigational in heart failure; leaves open the need for rigorous trials before clinical consideration.
INTRODUCTION failure (HF) is a global problem with an estimated prevalence of 38 million people worldwide; a number that is increasing the ageing of the population. heart failure is associated with high health expenditure, mostly because of cost of hospitalisations. The five year for individuals with heart failure is about 50%, and in advanced heart failure, the one year survival is as low as 22%, of therapy. modern history of therapy for heart failure with reduced ejection fraction began with the introduction of vasodilatation hydralazine plus isosorbide dinitrate. Research about heart failure is now quite active worldwide and many areas are being e.g. gene therapy, modification of function of micro RNAs by antagomirs, stem cell therapy besides development of pharmacological therapeutic agents.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: